Clinical Trial

RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease

Study acronym: REDRESS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the clinical and cost effectiveness of Haploidentical Stem Cell Transplantation (SCT) for adults with severe sickle cell disease (SCD), who have failed other therapies or are intolerant of existing therapies or require chronic transfusions to prevent on-going complications of SCD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-05-23.
Status change: Not Yet Recruiting → Recruiting 2023-05-09
Trial Details
NCT Number NCT05392894
Lead Sponsor King's College Hospital NHS Trust
Collaborators: King's College London, University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust, Guy's and St Thomas' NHS Foundation Trust, University College London Hospitals, Manchester University NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, Barts & The London NHS Trust, National Institute for Health Research, United Kingdom
Conditions Sickle Cell Disease
Enrollment 120 participants
Start Date 2023-02-23
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2023-05-10